irinotecan/kräkning

Länken sparas på Urklipp

Välj sorteringstyp

Sida 1 från 24 resultat

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

PRIMARY OBJECTIVES: I. To evaluate and compare overall survival (OS) in patients with resectable pancreatic adenocarcinoma treated with perioperative fluorouracil, irinotecan hydrochloride, leucovorin calcium and oxaliplatin (modified [m]FOLFIRINOX) and surgery versus up-front surgery followed by

Bioequivalence and the Tolerability and Antitumor Activity of Selinexor Combination Treatment

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Monotherapy Period For the Monotherapy Period of Study KCP-330-027, patients will be allocated to one of two test formulation treatment arms for once weekly dosing over a period of 3 weeks. A third test formulation of 100-mg oral suspension will be allocated on Week 3 to 6 patients in total out of

FOLFIRINOX for 2nd-line Treatment of BTC

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Biliary tract cancer (BTC) is a common term for malignant tumors that occur in gallbladder and bile duct, the path in which bile is released. According to the anatomical location, biliary tract cancer is divided into intrahepatic cholangiocarcinoma and extrahepatic

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Pancreatic cancer continues to be a highly lethal disease with an overall 5 year survival of only 8%. Since 2004, the incidence of pancreatic cancer has been increasing by 1.5% per year and it is estimated that there will be 53,670 new cases diagnosed in the United States in 2017, with 43,090

Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

At the same time as these results, triple therapies involving 5FU + oxiplatin + irinotecan have objectively shown a significant increase in overall survival of patients with metastatic pancreatic adenocarcinoma compared to gemcitabine alone (median of 11.1 months versus 6.8 months, HR = 0.57 [0.45 -

Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Lung cancer is the leading cause of cancer-related mortality worldwide. A report published by the WHO in February 2014, estimated there were 1.83 million new cases and 1.59 million deaths worldwide in 2012. The American Lung Association reports 399,431 Americans living with lung cancer, with an

Pilot Study to Assess the Safety and Pharmacokinetics of 70-150μm Drug Eluting Beads Loaded With Irinotecan (DEBIRI).

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

1. Recruitment: Suitable potential subjects will be identified, namely those who have failed first or second line chemotherapy agents. 2. Liver biopsy Right before the 1st transarterial chemoembolisation procedure, the liver metastases will be biopsied under ultrasound or CT guidance by the IR with

A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Pancreatic ductal adenocarcinoma is a highly lethal disease. It is estimated that in 2010 there were approximately 43,140 new cases in the United States and 36,800 deaths which ranks fourth among cancer related deaths . At diagnosis, roughly 17,000 of the initial 43,000 patients have disease which

A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Gemcitabine combined with 5FU may enhance the activity of 5-FU in vivo. Gemcitabine is an inhibitor of ribonucleotide reductase, an enzyme needed for synthesis of deoxynucleotides, and 5-FU interferes with dTTP synthesis by inhibition of thymidylate synthase (TS). It is likely that concomitant

A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

PRIMARY OBJECTIVES: I. To evaluate efficacy of the addition of fosaprepitant (fosaprepitant dimeglumine) in controlling acute and delayed vomiting with the standard prophylactic anti-emetic combination of 5-HT3 receptor antagonist and dexamethasone for gastrointestinal cancer patients receiving

Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Group I (Highly Emetogenic Chemotherapy): Patients that accepted chemotherapy including Cisplatin≥50mg/m2, Carmustine>250mg/m2, Cyclophosphamide>1500mg/m2, Dacarbazine>60mg/m2, Doxorubicin>60mg/m2, Epirubicin>90mg/m2, IFO≥10g/m2 or AC program. Group II (Moderately Emetogenic Chemotherapy): Patients

TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

About half of patients with newly diagnosed colorectal cancer will develop metastatic disease and, however, in spite of the significant progress in the therapeutical strategies for metastatic disease, virtually all patients will eventually succumb to their illness. Based on prior clinical data there

Panitumumab and Irinotecan for Malignant Gliomas

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

As the third most common cancer in incidence and second in mortality, colorectal cancer (CRC) significantly impacts the lives of many Americans.1 In 2008, it is estimated that 148,810 cases will be diagnosed and 49,960 patients will die from this disease. Approximately 20% of patients present with

Tidigare
1
2
Nästa

Gå med på vår
facebook-sida

Herbal & Natural Medicine

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

Fungerar på 55 språk
Växtbaserade botemedel som stöds av vetenskap
Örter igenkänning av bild
Interaktiv GPS-karta - märka örter på plats (kommer snart)
Läs vetenskapliga publikationer relaterade till din sökning
Sök efter medicinska örter efter deras effekter
Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning